Published in Br J Cancer on September 15, 2003
Molecular Biosensors for Detection of Bladder Cancer | NCT02957370
Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res (2012) 1.30
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer (2010) 1.26
Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer (2005) 1.12
Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front Physiol (2014) 1.11
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch (2011) 1.10
Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer (2011) 0.97
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett (2012) 0.95
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res (2011) 0.93
Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol (2013) 0.87
Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions. Ann Clin Biochem (2011) 0.87
Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell Biochem (2014) 0.86
Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant. Mol Cancer Ther (2008) 0.86
Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer. J Cancer Res Clin Oncol (2013) 0.85
The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer. Diagn Pathol (2013) 0.84
Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers. Curr Med Chem (2014) 0.82
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins. Biomark Cancer (2016) 0.77
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor. Mol Ther Oncolytics (2014) 0.77
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro. Drug Des Devel Ther (2014) 0.76
VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer. Int J Oncol (2013) 0.76
Dissecting the process of activation of cancer-promoting zinc-requiring ectoenzymes by zinc metalation mediated by ZnT transporters. J Biol Chem (2016) 0.75
DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening. Nucleic Acids Res (2016) 0.75
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer. Dis Markers (2016) 0.75
Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy. BMC Cancer (2016) 0.75
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics (1996) 2.34
A novel quasi-viral agent, MaTu, is a two-component system. Virology (1992) 2.22
Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A (1998) 2.20
Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol (1998) 1.99
Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res (1997) 1.96
Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer (1993) 1.89
Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol (1994) 1.69
Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res (2001) 1.41
Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer (2000) 1.37
Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology (2002) 1.35
The catalytic properties of human carbonic anhydrase IX. Biochem Biophys Res Commun (2001) 1.18
Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods (2003) 1.06
Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene (1994) 2.45
A novel quasi-viral agent, MaTu, is a two-component system. Virology (1992) 2.22
Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer (1993) 1.89
Human cell surface proteins selectively assembled into vesicular stomatitis virus virions. Virology (1983) 1.74
Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer (2000) 1.37
Host-cell repair of vaccinia virus and of double stranded RNA of encephalomyocarditis virus. Nat New Biol (1971) 1.09
Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. Neoplasma (2009) 0.94
Pseudotype particles of vesicular stomatitis virus with surface antigens of bovine leukaemia virus--VSV (BLV) -- as a sensitive probe for detecting antibodies in the sera of spontaneously infected cattle. Acta Virol (1978) 0.82
Immunotherapy of superficial bladder tumors: preliminary results with ImmuCyst--BCG Connaught, Toronto. Neoplasma (1994) 0.79
A rapid neutralization test for antibodies to bovine leukemia virus, with the use of rhabdovirus pseudotypes. J Natl Cancer Inst (1979) 0.79
Identification of MaTu-MX agent as a new strain of lymphocytic choriomeningitis virus (LCMV) and serological indication of horizontal spread of LCMV in human population. Virology (1999) 0.79
Pseudotypes of vesicular stomatitis virus with coat antigen of bovine leukaemia virus--VSV (BLV): antigenic surface mosaic and the roles of precipitating antibodies and polycations. Acta Virol (1980) 0.76
Host-cell repair of ultraviolet-irradiated pseudorabies virus in chick embryo cells. Acta Virol (1968) 0.76
Inactivation of single- and double-stranded ribonucleic acid of encephalomyocarditis virus by ultraviolet light. Acta Virol (1968) 0.76
[Mutations in tumor suppressor gene NBS1 in adult patients with malignancies]. Cas Lek Cesk (2006) 0.76
Comparison of the sensitivity to ultraviolet irradiation of reovirus 3 and some viruses of the Kemerovo group. Acta Virol (1975) 0.76
Rescue of presumptive viral information from human cells by a helper oncovirus. J Gen Virol (1986) 0.76
[Puerperal urinary bladder tamponade with massive right-sided renal hematuria]. Cesk Gynekol (1980) 0.75
A transmissible antigen detected in two cell lines derived from human tumours. J Gen Virol (1974) 0.75
[Results of surgery for breast cancer as established in two different periods of time]. Rozhl Chir (1977) 0.75
[5 primary tumors of the ureter]. Rozhl Chir (1986) 0.75
An unusual transmissible agent--MaTu. Arch Virol (1991) 0.75
[Renal injuries, their diagnosis and treatment (author's transl)]. Cas Lek Cesk (1978) 0.75
[Pseudotumor of the left epigastrium]. Cesk Radiol (1990) 0.75
Rescued human virus (RHV): association with melanoma. Int J Cancer (1988) 0.75
[Associated gunshot injuries of the urinary bladder and the extraperitoneal part of the rectum]. Rozhl Chir (1988) 0.75
[Indications for retroperitoneal lymphadenectomy in the comprehensive treatment of malignant tumors of the testis]. Rozhl Chir (1988) 0.75
The interfering activity of phage lysates. Folia Microbiol (Praha) (1966) 0.75
[Generalized melanoblastoma of the lower urinary tract]. Rozhl Chir (1994) 0.75
[Subungual exostoses]. Acta Chir Orthop Traumatol Cech (1969) 0.75
[Personal experience in the treatment of patients with stage I malignant nonseminomatous germ cell tumors of the testes]. Rozhl Chir (1988) 0.75
[The importance of transabdominal ultrasonography in determining the mass of prostatic adenomas]. Rozhl Chir (1988) 0.75
[The significance of uroflowmetry in evaluating urination disorders in women]. Cesk Gynekol (1985) 0.75
[A new method of treating male infertility: percutaneous transfemoral embolization of varicoceles with Vilan 500]. Rozhl Chir (1989) 0.75
[Urologic complications after surgery of sigmoid and rectal tumors]. Rozhl Chir (1981) 0.75
Vesicular stomatitis virus phenotypically mixed with retroviruses: an efficient detection method. Acta Virol (1983) 0.75
Monoclonal antibody against an antigen selectively assembled into vesicular stomatitis virus virions from HeLa cells. Int J Cancer (1984) 0.75
[Diverticula of the female urinary tract--still a problem in urogynecology]. Ceska Gynekol (2002) 0.75
[Our experiences with the therapy of open fractures of long bones by primary osteosynthesis (author's transl)]. Acta Chir Orthop Traumatol Cech (1975) 0.75
[Percutaneous nephrolithotomy]. Rozhl Chir (1994) 0.75
[Ultrasonography in urologic ambulatory care]. Rozhl Chir (1992) 0.75